Results 41 to 50 of about 26,340 (266)

What can we learn from SOCRATES: more questions than answers? [PDF]

open access: yes, 2017
This editorial refers to ‘Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) Study’, by B ...
Cleland, John G.F., Mueller, Christian
core   +1 more source

Blockade of the Neprilysin and Angiotensin Ameliorates Oxidative Stress in the Cardiovascular Target Tissues of Dexamethasone-induced Hypertensive Rats

open access: yesHaseki Tıp Bülteni, 2020
Aim:The imbalance between production of reactive oxygen species and antioxidant defense determines the degree of oxidative toxicity and severity of subsequent myocardial damage.We aimed to evaluate the anti-oxidative effects of neprilysin and angiotensin
Duygun Altıntaş Aykan   +4 more
doaj   +1 more source

Associations of Neprilysin and Its Coding Gene Variation With Hypertension in Chinese Adults. [PDF]

open access: yesJ Clin Hypertens (Greenwich)
ABSTRACT Neprilysin (NEP) degrades several vasoactive peptides and may contribute to blood pressure maintenance. This study aims to examine the associations between serum NEP levels and variants at its coding gene and hypertension in a general Chinese population.
Hu J   +14 more
europepmc   +2 more sources

Impacts of the combined exposure to seawater acidification and arsenic on the proteome of Crassostrea angulata and Crassostrea gigas [PDF]

open access: yes, 2018
Proteomic analysis was performed to compare the effects of Arsenic (As), seawater acidification (Low pH) and the combination of both stressors (Low pH + As) on Crassostrea angulata and Crassostrea gigas juveniles in the context of global environmental ...
Bebianno, Maria   +6 more
core   +1 more source

Breakthrough in Heart Failure therapy: LCZ696 combining ACE-Neprilysin inhibition

open access: yesAsian Journal of Medical Sciences, 2017
Background: Current Heart failure (HF) pharmacotherapy has been unsatisfactory in halting disease progression completely. Aims and Objective: To evaluate the role of LCZ696, a recent FDA-approved ACE -Neprilysin inhibitor (ARNi) in the management of ...
Sandeep Lahiry
doaj   +1 more source

Type of atrial fibrillation and clinical outcomes in patients with heart failure and reduced ejection fraction [PDF]

open access: yes, 2017
Background: Atrial fibrillation (AF) is common in heart failure (HF), but the outcome by type of AF is largely unknown. Objectives: This study investigated outcomes related to type of AF (paroxysmal, persistent or permanent, or new onset) in 2 ...
Abraham, William T.   +11 more
core   +3 more sources

Risk related to pre–diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial [PDF]

open access: yes, 2016
Background—The prevalence of pre–diabetes mellitus and its consequences in patients with heart failure and reduced ejection fraction are not known.
Cardoso, José Silva   +17 more
core   +1 more source

INNOVATIVE STRATEGY IN THERAPY OF CARDIAC INSUFFICIENCY

open access: yesМедицинский совет, 2017
The article is devoted to the innovative drug to treat chronic cardiac insufficiency – a combination of sakubitril neprilysin inhibitor and first type angiotension II receptor antagonist valsartan (sacubitril/valsartan).
N. A. Jaiani
doaj   +1 more source

‘Hearts and minds’: association, causation and implication of cognitive impairment in heart failure [PDF]

open access: yes, 2015
The clinical syndrome of heart failure is one of the leading causes of hospitalisation and mortality in older adults. An association between cognitive impairment and heart failure is well described but our understanding of the relationship between the ...
Cannon, Jane A.   +2 more
core   +4 more sources

The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study [PDF]

open access: yes, 2017
Aims: Progressive aortic stiffening eventually leads to left ventricular (LV) hypertrophy and heart failure if left untreated. Anti-hypertensive agents have been shown to reverse this to some extent. The effects of sacubitril/valsartan (LCZ696), a dual-
Aichner, Solveig   +15 more
core   +1 more source

Home - About - Disclaimer - Privacy